Rituximab for follicular lymphoma: watch and wait, watch and worry, or watch and live?
Publication
, Journal Article
LeBlanc, T; Kamal, A; Abernethy, A
Published in: Lancet Oncol
June 2014
Duke Scholars
Published In
Lancet Oncol
DOI
EISSN
1474-5488
Publication Date
June 2014
Volume
15
Issue
7
Start / End Page
e251 / e252
Location
England
Related Subject Headings
- Watchful Waiting
- Oncology & Carcinogenesis
- Male
- Lymphoma, Follicular
- Humans
- Female
- Antineoplastic Agents
- Antibodies, Monoclonal, Murine-Derived
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
LeBlanc, T., Kamal, A., & Abernethy, A. (2014). Rituximab for follicular lymphoma: watch and wait, watch and worry, or watch and live? Lancet Oncol, 15(7), e251–e252. https://doi.org/10.1016/S1470-2045(14)70215-3
LeBlanc, Thomas, Arif Kamal, and Amy Abernethy. “Rituximab for follicular lymphoma: watch and wait, watch and worry, or watch and live?” Lancet Oncol 15, no. 7 (June 2014): e251–52. https://doi.org/10.1016/S1470-2045(14)70215-3.
LeBlanc T, Kamal A, Abernethy A. Rituximab for follicular lymphoma: watch and wait, watch and worry, or watch and live? Lancet Oncol. 2014 Jun;15(7):e251–2.
LeBlanc, Thomas, et al. “Rituximab for follicular lymphoma: watch and wait, watch and worry, or watch and live?” Lancet Oncol, vol. 15, no. 7, June 2014, pp. e251–52. Pubmed, doi:10.1016/S1470-2045(14)70215-3.
LeBlanc T, Kamal A, Abernethy A. Rituximab for follicular lymphoma: watch and wait, watch and worry, or watch and live? Lancet Oncol. 2014 Jun;15(7):e251–e252.
Published In
Lancet Oncol
DOI
EISSN
1474-5488
Publication Date
June 2014
Volume
15
Issue
7
Start / End Page
e251 / e252
Location
England
Related Subject Headings
- Watchful Waiting
- Oncology & Carcinogenesis
- Male
- Lymphoma, Follicular
- Humans
- Female
- Antineoplastic Agents
- Antibodies, Monoclonal, Murine-Derived
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis